TENX logo

TENAX THERAPEUTICS INC

TENXNASDAQ
🏆 #4464 by market capUS Equity
$1.84▼ $0.02 (−1.08%)
Market closed · at close
🔔
Track TENX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.1%
7d▼ 3.7%
14d▲ 1.1%
30d▲ 0.0%
ytd▼ 84.9%
1y▼ 75.9%
🏦Market Cap
$49M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$1.83 – $1.85
52-Week Range
$1.31 – $19.40
Volume
$1.72B
Avg Volume
$2.12B
Shares Outstanding
26.5M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$2M
P/E Ratio
-1.2
P/S Ratio
0.0x
EPS (TTM)
$-1.28
Dividend Yield
0.00%
Dilution (1yr)
+156.8%

Why Investors Own TENX

  • ✓High-growth profile — revenue up +32.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 49% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TENX logo

TENAX THERAPEUTICS INC

TENX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$56M▲ +189.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$36M▲ +141.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
39.2M▲ +156.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$98M▲ +$3M YoY
StockOtter · stockotter.space

About TENAX THERAPEUTICS INC

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$1.99
▲ +8.3% Upside
High Target$2.42
Low Target$1.72
Based on 18 analysts

Latest News & Updates

🚀
Barron’s·2h ago

TENAX THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift TENX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

TENAX THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.